Evidence map›Paper›PMID 22493667›Full record

ArticlePloS one2012

Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine.

Anke M Mulder, Bridget Carragher, Victoria Towne, Yuan Meng, Yang Wang, Lance Dieter, Clinton S Potter, Michael W Washabaugh, Robert D Sitrin, Qinjian Zhao

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. NPJ vaccines · 2017
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Raising expectations for subunit vaccine.The Journal of infectious diseases · 2015
    Review
  19. Article
  20. The development of a recombinant hepatitis E vaccine HEV 239.Human vaccines & immunotherapeutics · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Anke M MulderDepartment of Research & Development, NanoImaging Services, La Jolla, California, United States of America. mulder@nanoimagingservices.com
Bridget Carragher
Victoria Towne
Yuan Meng
Yang Wang
Lance Dieter
Clinton S Potter
Michael W Washabaugh
Robert D Sitrin
Qinjian Zhao
United States Military Academy · USNanoImaging Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFundamental to vaccine development, manufacturing consistency, and product stability is an understanding of the vaccine structure-activity relationship. With the virus-like particle (VLP) approach for recombinant vaccines gaining popularity, there is growing demand for tools that define their key characteristics. We assessed a suite of non-intrusive VLP epitope structure and function characterization tools by application to the Hepatitis B surface antigen (rHBsAg) VLP-based vaccine. METHODOLOGY: The epitope-specific immune reactivity of rHBsAg epitopes to a given monoclonal antibody was monitored by surface plasmon resonance (SPR) and quantitatively analyzed on rHBsAg VLPs in-solution or bound to adjuvant with a competitive enzyme-linked immunosorbent assay (ELISA). The structure of recombinant rHBsAg particles was examined by cryo transmission electron microscopy (cryoTEM) and in-solution atomic force microscopy (AFM). PRINCIPAL

findingsSPR and competitive ELISA determined relative antigenicity in solution, in real time, with rapid turn-around, and without the need of dissolving the particulate aluminum based adjuvant. These methods demonstrated the nature of the clinically relevant epitopes of HBsAg as being responsive to heat and/or redox treatment. In-solution AFM and cryoTEM determined vaccine particle size distribution, shape, and morphology. Redox-treated rHBsAg enabled 3D reconstruction from CryoTEM images--confirming the previously proposed octahedral structure and the established lipid-to-protein ratio of HBsAg particles. Results from these non-intrusive biophysical and immunochemical analyses coalesced into a comprehensive understanding of rHBsAg vaccine epitope structure and function that was important for assuring the desired epitope formation, determinants for vaccine potency, and particle stability during vaccine design, development, and manufacturing. SIGNIFICANCE: Together, the methods presented here comprise a novel suite of non-intrusive VLP structural and functional characterization tools for recombinant vaccines. Key VLP structural features were defined and epitope-specific antigenicity was quantified while preserving epitope integrity and particle morphology. These tools should facilitate the development of other VLP-based vaccines.

Indexed as

Adjuvants, ImmunologicAntibodies, MonoclonalCryoelectron MicroscopyEnzyme-Linked Immunosorbent AssayEpitopesHepatitis BHepatitis B Surface AntigensHepatitis B VaccinesHepatitis B virusHumansMicroscopy, Atomic ForceModels, MolecularParticle SizeStructure-Activity RelationshipSurface Plasmon ResonanceVaccines, SyntheticAdjuvants, ImmunologicAntibodies, MonoclonalEpitopesHepatitis B Surface AntigensHepatitis B VaccinesVaccines, SyntheticVaccines, Virus-Like Particle

Identifiers

PMID22493667
PMCPMC3320896
OpenAlexW2059316367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.